Cognition Therapeutics, Inc.
CGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $235 | $0 |
| Gross Profit | $0 | $0 | -$235 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $41,676 | $37,196 | $30,324 | $18,572 |
| G&A Expenses | $12,290 | $13,528 | $13,227 | $10,026 |
| SG&A Expenses | $12,290 | $13,528 | $13,227 | $10,026 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$235 | $0 |
| Operating Expenses | $53,966 | $50,724 | $43,316 | $28,598 |
| Operating Income | -$53,966 | -$50,724 | -$43,551 | -$28,598 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $19,995 | $24,936 | $22,154 | $16,882 |
| Pre-Tax Income | -$33,971 | -$25,788 | -$21,397 | -$11,716 |
| Tax Expense | $0 | $0 | -$22,154 | $0 |
| Net Income | -$33,971 | -$25,788 | $757 | -$11,716 |
| % Margin | – | – | – | – |
| EPS | -0.85 | -0.86 | -0.74 | -0.73 |
| % Growth | 1.2% | -16.2% | -1.4% | – |
| EPS Diluted | -0.85 | -0.86 | -0.74 | -0.73 |
| Weighted Avg Shares Out | 39,730 | 29,986 | 28,992 | 22,230 |
| Weighted Avg Shares Out Dil | 39,730 | 30,029 | 28,992 | 22,230 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $27 | $22,217 | $17,447 |
| Interest Expense | $25 | $0 | $28 | $893 |
| Depreciation & Amortization | $266 | $252 | $235 | $93 |
| EBITDA | -$33,680 | -$25,509 | -$21,134 | -$10,730 |
| % Margin | – | – | – | – |